Physician profile
Jon D Rosser
NPI 1528052818
$7,554.02
in general payments reported to CMS, 2019-2025
25 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,805 · 2020: $101 · 2021: $259 · 2022: $82.58 · 2023: $134 · 2024: $66.97 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,653.68 | 2019 | |
| Ethicon US, LLC | $198.35 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.39 | 2021-2023 | Gattex |
| Axonics, INC. | $77.60 | 2021-2022 | |
| Medtronic, INC. | $55.82 | 2023-2024 | Interstim, Parietene Ds |
| Myriad Genetic Laboratories, INC. | $31.70 | 2024 | Myrisk |
| Baudax Bio INC. | $29.35 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $27.52 | 2025 | Exparel |
| Kowa Pharmaceuticals America, INC. | $27.52 | 2022-2023 | Seglentis |
| La Jolla Pharmaceutical Company | $26.23 | 2020-2023 | Xerava |
| W. L. Gore & Associates, INC. | $26.00 | 2025 | Gore Enform Intraperitoneal Biomaterial |
| Boston Scientific Corporation | $23.38 | 2019-2020 | |
| Kerecis Limited | $19.49 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Redhill Biopharma INC. | $18.31 | 2020 | |
| Medtronic USA, INC. | $16.87 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $16.72 | 2025 | Zynrelef |
| Solventum Corporation | $15.28 | 2025 | V.A.C. Veraflo, Prevena |
| Concordia Pharmaceuticals INC. | $15.20 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.10 | 2024 | Rebyota |
| Convatec INC. | $13.87 | 2020 | |
| Lsi Solutions INC | $12.35 | 2020 | |
| Baxter Healthcare | $11.20 | 2021 | |
| Zyla Life Sciences, INC. | $11.04 | 2020 | |
| Prescient Surgical | $10.98 | 2019 | |
| Thd America, INC. | $10.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Rosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.